HK1253517B - 抗病毒化合物 - Google Patents

抗病毒化合物

Info

Publication number: HK1253517B
Authority: HK; Hong Kong
Prior art keywords: antiviral compounds; antiviral; compounds
Prior art date: 2009-05-13

Application number

HK18112717.7A

Other languages

English (en)

Other versions

HK1253517A1 (zh

Inventor

Hongyan Guo

Darryl Kato

Thorstens A Kirschberg

Hongtae Liu

John O Link

Michael L Mitchell

Jay P Parrish

Neil Squires

Jianyu Sun

James Taylor

Elizabeth M Bacon

Eda Canales

Aesop Cho

Jeromy J Cottell

Manoj C Desai

Randall L Halcomb

Evan S Krygowski

Scott E Lazerwith

Qi Liu

Richard Mackman

Hyung-Jung Pyun

Joseph H Saugier

James D Trenkle

Winston C Tse

Randall W Vivian

Scott D Schroeder

William J Watkins

Lianhong Xu

Zheng-Yu Yang

Terry Kellar

Xiaoning Sheng

Michael O’Neil Hanrahan Clarke

Chien-Hung Chou

Michael Graupe

Haolun Jin

Ryan Mcfadden

Michael R Mish

Samuel E Metobo

Barton W Phillips

Chandrasekar Venkataramani

Chuong U Kim

Original Assignee

Gilead Pharmasset Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-13

Filing date

2018-10-05

Publication date

2020-04-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42645241&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1253517(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-10-05 Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc

2019-06-21 Publication of HK1253517A1 publication Critical patent/HK1253517A1/zh

2020-04-24 Publication of HK1253517B publication Critical patent/HK1253517B/zh

Links

230000000840 anti-viral effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Peptides Or Proteins (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

HK18112717.7A 2009-05-13 2018-10-05 抗病毒化合物 HK1253517B (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US17797209P	2009-05-13	2009-05-13
US22474509P	2009-07-10	2009-07-10
US23876009P	2009-09-01	2009-09-01

Publications (2)

Publication Number	Publication Date
HK1253517A1 HK1253517A1 (zh)	2019-06-21
HK1253517B true HK1253517B (zh)	2020-04-24

Family

ID=42645241

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
HK15108271.6A HK1207638A1 (zh)	2009-05-13	2012-04-02	抗病毒化合物
HK12103256.9A HK1162518A1 (zh)	2009-05-13	2012-04-02	抗病毒化合物
HK16111614.5A HK1223365A1 (zh)	2009-05-13	2016-10-06	抗病毒化合物
HK18112717.7A HK1253517B (zh)	2009-05-13	2018-10-05	抗病毒化合物

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
HK15108271.6A HK1207638A1 (zh)	2009-05-13	2012-04-02	抗病毒化合物
HK12103256.9A HK1162518A1 (zh)	2009-05-13	2012-04-02	抗病毒化合物
HK16111614.5A HK1223365A1 (zh)	2009-05-13	2016-10-06	抗病毒化合物

Country Status (40)

Country	Link
US (8)	US8088368B2 (zh)
EP (6)	EP2873665B1 (zh)
JP (7)	JP5582662B2 (zh)
KR (8)	KR20140122705A (zh)
CN (8)	CN109020961A (zh)
AP (2)	AP3622A (zh)
AR (1)	AR076765A1 (zh)
AU (1)	AU2010249043B2 (zh)
BR (3)	BRPI1010795B1 (zh)
CA (2)	CA2761258C (zh)
CL (1)	CL2011002825A1 (zh)
CO (1)	CO6470842A2 (zh)
CY (4)	CY1116942T1 (zh)
DK (3)	DK3002281T3 (zh)
EA (5)	EA021974B1 (zh)
EC (1)	ECSP11011517A (zh)
ES (4)	ES2596247T3 (zh)
FR (1)	FR16C0005I2 (zh)
HK (4)	HK1207638A1 (zh)
HR (3)	HRP20151000T8 (zh)
HU (4)	HUE030465T2 (zh)
IL (5)	IL216254A (zh)
LT (3)	LT2873665T (zh)
ME (3)	ME02536B (zh)
MX (6)	MX2011012058A (zh)
NL (1)	NL300796I2 (zh)
NO (3)	NO3002281T3 (zh)
NZ (3)	NZ706236A (zh)
PE (2)	PE20120509A1 (zh)
PL (4)	PL2873665T3 (zh)
PT (4)	PT2430014E (zh)
RS (3)	RS56654B8 (zh)
SG (2)	SG10201402280QA (zh)
SI (4)	SI3309157T1 (zh)
SM (2)	SMT201500284B (zh)
TW (7)	TW202042807A (zh)
UA (1)	UA121454C2 (zh)
UY (1)	UY32629A (zh)
WO (1)	WO2010132601A1 (zh)
ZA (1)	ZA201108436B (zh)

Families Citing this family (202)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3521297B1 (en)	2003-05-30	2021-12-22	Gilead Pharmasset LLC	Modified fluorinated nucleoside analogues
KR20150089099A (ko) *	2007-07-05	2015-08-04	어레이 바이오파마 인크.	Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
KR20110098779A (ko) *	2008-12-03	2011-09-01	프레시디오 파마슈티칼스, 인코포레이티드	Ｈｃｖｎｓ5ａ의 억제제
BRPI0922366B8 (pt) *	2008-12-03	2021-05-25	Presidio Pharmaceuticals Inc	composto, composição farmacêutica e uso de um composto
MX2011006332A (es)	2008-12-23	2011-06-27	Abbott Lab	Compuestos antivirales.
US8546405B2 (en)	2008-12-23	2013-10-01	Abbott Laboratories	Anti-viral compounds
US8314135B2 (en)	2009-02-09	2012-11-20	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole antivirals
US8242156B2 (en)	2009-02-17	2012-08-14	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole derivatives
US8394968B2 (en)	2009-02-17	2013-03-12	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8188132B2 (en)	2009-02-17	2012-05-29	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole derivatives
US8637561B2 (en) *	2009-02-17	2014-01-28	Enanta Pharmaceuticals, Inc.	Linked diimidazole derivatives
TWI438200B (zh) *	2009-02-17	2014-05-21	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
EP2398474A4 (en) *	2009-02-23	2012-12-05	Presidio Pharmaceuticals Inc	HCV NS5A SHEMMER
US8673954B2 (en)	2009-02-27	2014-03-18	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
US9765087B2 (en)	2009-02-27	2017-09-19	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
US8101643B2 (en) *	2009-02-27	2012-01-24	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
EP2410841A4 (en)	2009-03-27	2012-10-24	Presidio Pharmaceuticals Inc	SUBSTITUTED BICYCLIC HCV INHIBITORS
US8796466B2 (en)	2009-03-30	2014-08-05	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TW201038559A (en) *	2009-04-09	2010-11-01	Bristol Myers Squibb Co	Hepatitis C virus inhibitors
US8143414B2 (en)	2009-04-13	2012-03-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP5734956B2 (ja)	2009-04-15	2015-06-17	アッヴィ・インコーポレイテッド	抗ウィルス化合物
CN102414199B (zh) *	2009-04-24	2014-03-05	泰博特克药品公司	二芳基醚
AU2010249080A1 (en) *	2009-05-12	2012-01-12	Merck Sharp & Dohme Corp.	Fused tricyclic aryl compounds useful for the treatment of viral diseases
RS56654B8 (sr)	2009-05-13	2021-06-30	Gilead Pharmasset Llc	Antiviralna jedinjenja
US8138215B2 (en) *	2009-05-29	2012-03-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP2012528194A (ja) *	2009-05-29	2012-11-12	メルク・シャープ・アンド・ドーム・コーポレーション	Ｃ型肝炎などの疾患を処置するための３つの整列型アリール部分で構成された抗菌性化合物
WO2010138791A1 (en) *	2009-05-29	2010-12-02	Schering Corporation	Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8211928B2 (en)	2009-05-29	2012-07-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9394279B2 (en)	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds
SG171708A1 (en)	2009-06-11	2011-07-28	Abbott Lab	Anti-viral compounds to treat hcv infection
US8716454B2 (en)	2009-06-11	2014-05-06	Abbvie Inc.	Solid compositions
US8937150B2 (en)	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
US8609648B2 (en)	2009-07-02	2013-12-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
EP2454254A2 (en)	2009-07-16	2012-05-23	Vertex Pharmaceuticals Incorporated	Benzimidazole analogues for the treatment or prevention of flavivirus infections
AU2010280712B2 (en) *	2009-08-07	2015-10-22	Janssen Sciences Ireland Uc	Bis-benzimidazole derivatives as hepatitis C virus inhibitors
AU2010280711A1 (en) *	2009-08-07	2012-02-09	Janssen Sciences Ireland Uc	Phenyl ethynyl derivatives as hepatitis C virus inhibitors
EP3006441A1 (en)	2009-09-04	2016-04-13	Janssen Pharmaceuticals, Inc.	Ns5a inhibitors
US8703938B2 (en) *	2009-09-11	2014-04-22	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8927709B2 (en) *	2009-09-11	2015-01-06	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8822700B2 (en) *	2009-09-11	2014-09-02	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8759332B2 (en) *	2009-09-11	2014-06-24	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8815928B2 (en) *	2009-09-11	2014-08-26	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US9156818B2 (en) *	2009-09-11	2015-10-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
EP2475254A4 (en) *	2009-09-11	2013-05-22	Enanta Pharm Inc	HEPATITIS C-VIRUS HEMMER
UA108211C2 (uk)	2009-11-04	2015-04-10	Янссен Рід Айрленд	Бензімідазолімідазольні похідні
US20110274648A1 (en) *	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110269956A1 (en)	2009-11-11	2011-11-03	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110281910A1 (en) *	2009-11-12	2011-11-17	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
CN102482269B (zh) *	2009-12-04	2015-07-29	财团法人卫生研究院	脯氨酸衍生物
US8653070B2 (en)	2009-12-14	2014-02-18	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CN104530079B (zh) *	2009-12-18	2017-10-20	北京凯因科技股份有限公司	C型肝炎病毒复制的新型抑制剂
CN102822175A (zh) *	2009-12-18	2012-12-12	埃迪尼克斯医药公司	5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
US20130072523A1 (en) *	2009-12-24	2013-03-21	Vertex Pharmaceuticals Incorporated	Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en)	2009-12-30	2013-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8933110B2 (en)	2010-01-25	2015-01-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
KR20120107529A (ko)	2010-01-25	2012-10-02	이난타 파마슈티칼스, 인코포레이티드	Ｃ형 간염 바이러스 억제제
JP2013518062A (ja) *	2010-01-28	2013-05-20	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃ型肝炎阻害化合物
US8178531B2 (en) *	2010-02-23	2012-05-15	Enanta Pharmaceuticals, Inc.	Antiviral agents
US8623814B2 (en) *	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
JP2013521279A (ja) *	2010-03-04	2013-06-10	エナンタファーマシューティカルズインコーポレイテッド	Ｈｃｖ複製の阻害剤としての医薬併用剤
CN102869657A (zh) *	2010-03-24	2013-01-09	沃泰克斯药物股份有限公司	用于治疗或预防黄病毒感染的类似物
WO2011119860A1 (en) *	2010-03-24	2011-09-29	Vertex Pharmaceuticals Incorporated	Analogues for the treatment or prevention of flavivirus infections
WO2011127350A1 (en)	2010-04-09	2011-10-13	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
US9125904B1 (en)	2010-05-11	2015-09-08	Achillion Pharmaceuticals, Inc.	Biphenyl imidazoles and related compounds useful for treating HCV infections
EP2575475A4 (en) *	2010-05-28	2013-11-27	Presidio Pharmaceuticals Inc	HCV NS5A INHIBITORS
EP2575819A4 (en)	2010-06-04	2013-11-27	Enanta Pharm Inc	INHIBITORS OF HEPATITIS C VIRUS
CA2802067A1 (en) *	2010-06-09	2011-12-15	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a protein
NZ605440A (en)	2010-06-10	2014-05-30	Abbvie Bahamas Ltd	Solid compositions comprising an hcv inhibitor
US8697704B2 (en)	2010-08-12	2014-04-15	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US20120195857A1 (en) *	2010-08-12	2012-08-02	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
WO2012020036A1 (en) *	2010-08-13	2012-02-16	F. Hoffmann-La Roche Ag	Hepatitis c virus inhibitors
US8859595B2 (en)	2010-08-26	2014-10-14	Rfs Pharma, Llc	Potent and selective inhibitors of hepatitis C virus
US8999967B2 (en)	2010-09-29	2015-04-07	Presidio Pharmaceuticals, Inc.	Tricyclic fused ring inhibitors of hepatitis C
KR20190012271A (ko) *	2010-11-17	2019-02-08	길리애드 파마셋 엘엘씨	항바이러스 화합물
RU2452735C1 (ru) *	2010-11-30	2012-06-10	Александр Васильевич Иващенко	Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
EP2651925A4 (en) *	2010-12-15	2014-06-18	Abbvie Inc	ANTI-VIRAL COMPOUNDS
EP2651927A4 (en) *	2010-12-15	2014-06-04	Abbvie Inc	ANTIVIRAL CONNECTIONS
US20140364616A1 (en) *	2010-12-15	2014-12-11	Abbvie Inc.	Anti-viral compounds
CA2822037A1 (en)	2010-12-20	2012-06-28	Gilead Sciences, Inc.	Methods for treating hcv
WO2012087976A2 (en) *	2010-12-21	2012-06-28	Intermune, Inc.	Novel inhibitors of hepatitis c virus replication
US8552047B2 (en)	2011-02-07	2013-10-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP2012188400A (ja) *	2011-03-11	2012-10-04	Tosoh Corp	ジチエノベンゾジチオフェンの製造方法
WO2012122716A1 (en)	2011-03-17	2012-09-20	Merck Sharp & Dohme Corp.	Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US8835456B1 (en)	2011-03-18	2014-09-16	Achillion Pharmaceuticals, Inc.	NS5A inhibitors useful for treating HCV
US20120252721A1 (en) *	2011-03-31	2012-10-04	Idenix Pharmaceuticals, Inc.	Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9546160B2 (en) *	2011-05-12	2017-01-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
EP2709455A4 (en)	2011-05-18	2014-11-05	Enanta Pharm Inc	PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES
HUE029326T2 (hu)	2011-05-27	2017-02-28	Achillion Pharmaceuticals Inc	Szubsztituált alifánok, ciklofánok, heterafánok, heterofánok, hetero-heterafánok és metallocének, amelyek alkalmasak HCV fertõzések kezelésére
WO2013007106A1 (zh)	2011-07-09	2013-01-17	广东东阳光药业有限公司	作为丙型肝炎病毒抑制剂的螺环化合物
WO2013021344A1 (en)	2011-08-08	2013-02-14	Lupin Limited	Imidazole derivatives as antiviral agents
WO2013025975A1 (en) *	2011-08-17	2013-02-21	Glaxosmithkline Llc	Combination treatments for hepatitis c
MX2014002171A (es) *	2011-08-24	2014-04-25	Glaxosmithkline Llc	Tratamientos de combinacion para hepatitis c.
WO2013030750A1 (en)	2011-09-01	2013-03-07	Lupin Limited	Antiviral compounds
DE202012013074U1 (de) *	2011-09-16	2014-10-29	Gilead Pharmasset Lcc	Zusammensetzungen zur Behandlung von HCV
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
ES2527510T1 (es) *	2011-10-21	2015-01-26	Abbvie Inc.	Métodos para el tratamiento del VHC que comprenden al menos dos agentes antivirales de acción directa, ribavirina pero no interferón
DE112012003457T5 (de)	2011-10-21	2015-03-12	Abbvie Inc.	Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV)
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
JP6082747B2 (ja)	2011-11-03	2017-02-15	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	フラグメント｛２−［４−（ビフェニル−４−イル）−１ｈ−イミダゾ−２−イル］ピロリジン−１−カルボニルメチル｝アミンを含む棒状ｃ型肝炎ウイルス阻害剤
US20130164260A1 (en)	2011-11-16	2013-06-27	Gilead Sciences, Inc.	Antiviral compounds
US9126986B2 (en)	2011-12-28	2015-09-08	Janssen Sciences Ireland Uc	Hetero-bicyclic derivatives as HCV inhibitors
US9034832B2 (en)	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
US20130172239A1 (en) *	2011-12-29	2013-07-04	Abbvie Inc.	Solid compositions
US9326973B2 (en)	2012-01-13	2016-05-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CA2862755A1 (en) *	2012-02-10	2013-08-15	Lupin Limited	Antiviral compounds with a dibenzooxaheterocycle moiety
US8673926B2 (en) *	2012-02-14	2014-03-18	University Of Georgia Research Foundation, Inc.	Spiro[2.4]heptanes for treatment of flaviviridae infections
ITMI20120424A1 (it)	2012-03-19	2013-09-20	Rottapharm Spa	Composti chimici
CN104302639B (zh)	2012-04-25	2017-03-29	施万生物制药研发Ip有限责任公司	作为c型肝炎病毒抑制剂的哌嗪‑哌啶化合物
US9066944B2 (en)	2012-04-25	2015-06-30	Theravance Biopharma R&D Ip, Llc	Hepatitis C virus inhibitors
US9079887B2 (en) *	2012-05-16	2015-07-14	Gilead Sciences, Inc.	Antiviral compounds
US20130309196A1 (en)	2012-05-16	2013-11-21	Gilead Sciences, Inc.	Antiviral compounds
US9056860B2 (en)	2012-06-05	2015-06-16	Gilead Pharmasset Llc	Synthesis of antiviral compound
US8969588B2 (en) *	2012-06-05	2015-03-03	Gilead Pharmasset Llc	Solid forms of an antiviral compound
TWI610916B (zh) *	2012-08-03	2018-01-11	廣東東陽光藥業有限公司	作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
TW201412709A (zh) *	2012-09-28	2014-04-01	Sunshine Lake Pharma Co Ltd	作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用
CN103848818B (zh) *	2012-11-29	2017-03-15	广东东阳光药业有限公司	作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
WO2014082381A1 (en) *	2012-11-29	2014-06-05	Sunshine Lake Pharma Co., Ltd.	Spiro ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
US9416139B2 (en)	2012-11-29	2016-08-16	Sunshine Lake Pharma Co., Ltd.	Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
CN103880823B (zh) *	2012-12-21	2017-12-05	广东东阳光药业有限公司	作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用
CN104144682A (zh)	2013-01-31	2014-11-12	吉利德法莫赛特有限责任公司	两个抗病毒化合物的联用制剂
RU2518369C1 (ru) *	2013-02-07	2014-06-10	Общество с ограниченной ответственностью "Интеллектуальный Диалог"	Алкил [2-(2-{5-[4-(4-{2-[1-(2-метоксикарбониламино-ацетил)-пирролидин-2-ил]-3н-имидазол-4-ил}-фенил)-бута-1,3-диинил]-1н-имидазол-2-ил}-пирролидин-1-ил)-2-оксо-этил]-карбамат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
RU2507201C1 (ru) *	2013-02-07	2014-02-20	Александр Васильевич Иващенко	Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
TW201439060A (zh) *	2013-02-27	2014-10-16	Sunshine Lake Pharma Co Ltd	作爲丙型肝炎抑制劑的橋環化合物及其藥物組合物和用途
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
WO2014197400A1 (en)	2013-06-04	2014-12-11	Gilead Pharmasset Llc	Preventing and treating recurrence of hcv infection after liver transplant
CN111116563B (zh) *	2013-06-06	2023-07-04	上海爱博医药科技有限公司	抑制丙肝病毒的化合物、药物组合物及其应用
US20150023913A1 (en)	2013-07-02	2015-01-22	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US9717712B2 (en)	2013-07-02	2017-08-01	Bristol-Myers Squibb Company	Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
EP3021845A1 (en)	2013-07-17	2016-05-25	Bristol-Myers Squibb Company	Combinations comprising biphenyl derivatives for use in the treatment of hcv
ES2900570T3 (es)	2013-08-27	2022-03-17	Gilead Pharmasset Llc	Formulación de combinación de dos compuestos antivirales
CN104418785A (zh) *	2013-09-05	2015-03-18	浙江九洲药业股份有限公司	一种药物中间体的制备方法
US20160229866A1 (en)	2013-09-20	2016-08-11	Idenix Pharmaceuticals Inc.	Hepatitis c virus inhibitors
CN104610272B (zh) *	2013-11-05	2017-03-29	上海唐润医药科技有限公司	环状黄酮或异黄酮类化合物及其用途
KR101561964B1 (ko)	2013-11-15	2015-10-20	한국과학기술연구원	옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
WO2015084741A2 (en)	2013-12-02	2015-06-11	Gilead Pharmasset Llc	Methods of treating hepatitis c virus infection in subjects with cirrhosis
TW201609785A (zh)	2013-12-23	2016-03-16	吉李德製藥公司	固體型之抗病毒化合物
CN104725365B (zh) *	2013-12-23	2019-02-26	南京圣和药业股份有限公司	丙型肝炎病毒抑制剂及其应用
EP3091010A4 (en) *	2013-12-31	2017-10-04	Nanjing Sanhome Pharmaceutical Co., Ltd.	9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene hepatitis c virus inhibitor and application thereof
EP3089757A1 (en)	2014-01-03	2016-11-09	AbbVie Inc.	Solid antiviral dosage forms
WO2015110048A1 (en)	2014-01-23	2015-07-30	Sunshine Lake Pharma Co., Ltd.	Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
CN108084172A (zh) *	2014-02-21	2018-05-29	常州寅盛药业有限公司	抗丙肝病毒化合物
CN104860931A (zh) *	2014-02-21	2015-08-26	常州寅盛药业有限公司	丙肝病毒抑制剂及其制药用途
WO2015184644A1 (zh) *	2014-06-06	2015-12-10	爱博新药研发(上海)有限公司	抑制丙肝病毒的化合物、药物组合物及其应用
TWI721947B (zh)	2014-06-11	2021-03-21	美商基利法瑪席特有限責任公司	抗病毒化合物的固態形式
CN104140417B (zh) *	2014-06-11	2016-04-06	苏州景泓生物技术有限公司	合成gs5885用的中间体的先期化合物的合成方法
CN105524049B (zh) *	2014-09-28	2018-11-06	正大天晴药业集团股份有限公司	氘代的丙型肝炎病毒ns5a蛋白抑制剂
CN104513147B (zh) *	2014-11-20	2016-05-11	上海众强药业有限公司	芴乙酮衍生物的制备方法
TWI675029B (zh) *	2014-12-16	2019-10-21	大陸商廣東東陽光藥業有限公司	作為丙型肝炎抑制劑的橋環化合物及其製備方法
WO2016103232A1 (en) *	2014-12-24	2016-06-30	Granules India Limited	An improved process for the preparation of hcv inhibitor
CN104530016A (zh) *	2014-12-25	2015-04-22	上海泓博智源医药技术有限公司	一种雷迪帕韦的制备方法及其中间体
BR112017013858A2 (pt)	2014-12-26	2018-02-27	Univ Emory	n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
EP3256104A1 (en)	2015-02-13	2017-12-20	Sandoz AG	Pharmaceutical compositions comprising ledipasvir and sofosbuvir
CN105985355B (zh) *	2015-03-01	2020-05-05	南京圣和药业股份有限公司	稠合三环类肝炎病毒抑制剂及其应用
PL3321265T3 (pl)	2015-03-04	2020-11-16	Gilead Sciences, Inc.	Związki 4,6-diamino-pirydo[3,2-d]pirymidynowe i ich wykorzystanie jako modulatorów receptorów toll-podobnych
WO2016145269A1 (en)	2015-03-12	2016-09-15	Teva Pharmaceuticals International Gmbh	Solid state forms ledipasvir and processes for preparation of ledipasvir
CN104829599B (zh) *	2015-03-17	2017-06-09	上海众强药业有限公司	雷迪帕韦及其衍生物的制备方法及用于制备雷迪帕韦的中间体化合物
US20160375017A1 (en)	2015-06-26	2016-12-29	Abbvie Inc.	Solid Pharmaceutical Compositions for Treating HCV
CN105017228A (zh) *	2015-07-03	2015-11-04	上海众强药业有限公司	一种雷迪帕韦中间体单硫酸盐、其晶型及其制备方法
NZ736978A (en)	2015-07-24	2019-06-28	Newlink Genetics Corp	Salts and prodrugs of 1-methyl-d-tryptophan
WO2017023631A1 (en)	2015-08-06	2017-02-09	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
KR101919194B1 (ko) *	2015-09-15	2018-11-15	주식회사 엘지화학	헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
CN105294713A (zh) *	2015-10-09	2016-02-03	重庆康施恩化工有限公司	Velpatasvir中间体及其制备方法
WO2017072596A1 (en)	2015-10-26	2017-05-04	Optimus Drugs (P) Ltd	An improved process for the preparation of ledipasvir
WO2017072714A1 (en)	2015-10-30	2017-05-04	Lupin Limited	Stable ledipasvir premix and process of preparation thereof
WO2017076201A1 (zh) *	2015-11-06	2017-05-11	江苏豪森药业集团有限公司	Hcv抑制剂、其制备方法与应用
CN106117187B (zh) *	2016-01-12	2019-01-01	深圳市塔吉瑞生物医药有限公司	一种丙型肝炎病毒抑制剂、药物组合物及其应用
WO2017134548A1 (en)	2016-02-01	2017-08-10	Lupin Limited	Process for the preparation of ledipasvir and intermediates thereof
WO2017145028A1 (en) *	2016-02-26	2017-08-31	Glenmark Pharmaceuticals Limited	Process for preparation of ledipasvir
WO2017184670A2 (en)	2016-04-22	2017-10-26	Gilead Sciences, Inc.	Methods for treating zika virus infections
WO2017189978A1 (en)	2016-04-28	2017-11-02	Emory University	Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN109562113A (zh)	2016-05-10	2019-04-02	C4医药公司	用于靶蛋白降解的螺环降解决定子体
EP3454856A4 (en)	2016-05-10	2019-12-25	C4 Therapeutics, Inc.	HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197046A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	C3-carbon linked glutarimide degronimers for target protein degradation
WO2017195147A1 (en)	2016-05-12	2017-11-16	Lupin Limited	Process for the preparation of ledipasvir and intermediates thereof
JP6770098B2 (ja)	2016-05-27	2020-10-14	ギリアードサイエンシーズ，インコーポレイテッド	Ｎｓ５ａ、ｎｓ５ｂまたはｎｓ３阻害剤を使用する、ｂ型肝炎ウイルス感染症を処置するための方法
BR102017011025A2 (pt)	2016-06-02	2017-12-19	Gilead Pharmasset Llc	Formulation of combination of three antiviral compounds
CN107663196A (zh) *	2016-07-27	2018-02-06	广东东阳光药业有限公司	制备化合物的方法
WO2018035410A1 (en) *	2016-08-19	2018-02-22	Temple University-Of The Commonwealth System Of Higher Education	Compositions and methods of treatment using expanded-size dna analogs
SI3507276T1 (sl)	2016-09-02	2022-01-31	Gilead Sciences, Inc.	Spojine modulatorja toličnih receptorjev
WO2018045150A1 (en)	2016-09-02	2018-03-08	Gilead Sciences, Inc.	4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CN106632275B (zh) *	2016-12-20	2018-03-06	上海同昌生物医药科技有限公司	一种雷迪帕韦的制备方法及制备雷迪帕韦的中间体
RU2650610C1 (ru)	2017-02-28	2018-04-16	Васильевич Иващенко Александр	Противовирусная композиция и способ ее применения
US10392370B2 (en)	2017-03-13	2019-08-27	Optimus Drugs Pvt Ltd	Process for the preparation of Daclatasvir dihydrochloride and its intermediates
JOP20180040A1 (ar)	2017-04-20	2019-01-30	Gilead Sciences Inc	مثبطات pd-1/pd-l1
KR20200035234A (ko)	2017-05-12	2020-04-02	마발론 테라퓨틱스 리미티드	그룹 ii 대사성 글루타메이트 수용체의 알로스테릭 조절제로서의 치환된 헤테로사이클릭 화합물
MX2020005392A (es)	2017-12-07	2020-12-07	Univ Emory	N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos.
MX2020008404A (es)	2018-02-13	2020-09-25	Gilead Sciences Inc	Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
CA3093130C (en)	2018-04-19	2023-10-17	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
US20210267932A1 (en) *	2018-05-15	2021-09-02	University Of Louisville Research Foundation, Inc.	Compounds, compositions, methods of using, and methods for preparing compounds
AU2019301811B2 (en)	2018-07-13	2022-05-26	Gilead Sciences, Inc.	PD-1/PD-L1 inhibitors
JP7158577B2 (ja)	2018-10-24	2022-10-21	ギリアードサイエンシーズ，インコーポレイテッド	Ｐｄ－１／ｐｄ－ｌ１阻害剤
WO2020219808A1 (en) *	2019-04-25	2020-10-29	Beta Pharma, Inc.	Dicarbamate inhibitors of ns5a for treatment of hepatitis c virus infections and related diseases
US20220305115A1 (en)	2019-06-18	2022-09-29	Janssen Sciences Ireland Unlimited Company	Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
WO2021209563A1 (en)	2020-04-16	2021-10-21	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
EP4079748A1 (en)	2021-04-23	2022-10-26	Insusense ApS	Modulators of sortilin activity
EP4089102A1 (en)	2021-05-14	2022-11-16	Insusense ApS	Modulators of sortilin activity
CA3219397A1 (en) *	2021-05-21	2022-11-24	Gilead Sciences, Inc.	Tetracyclic compounds for the treatment of zika virus infection
PE20240775A1 (es)	2021-07-09	2024-04-17	Aligos Therapeutics Inc	Compuestos antivirales
WO2023043816A1 (en) *	2021-09-17	2023-03-23	Aligos Therapeutics, Inc.	Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
WO2023154528A1 (en) *	2022-02-11	2023-08-17	Wave Life Sciences Ltd.	Stereoselective technologies for chiral compounds

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816570A (en)	1982-11-30	1989-03-28	The Board Of Regents Of The University Of Texas System	Biologically reversible phosphate and phosphonate protective groups
US4968788A (en)	1986-04-04	1990-11-06	Board Of Regents, The University Of Texas System	Biologically reversible phosphate and phosphonate protective gruops
WO1991019721A1 (en)	1990-06-13	1991-12-26	Arnold Glazier	Phosphorous produgs
DE69129650T2 (de)	1990-09-14	1999-03-25	Acad Of Science Czech Republic	Wirkstoffvorläufer von Phosphonaten
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
AU2005274700B2 (en)	2004-07-16	2011-11-10	Gilead Sciences, Inc.	Antiviral compounds
US7323447B2 (en) *	2005-02-08	2008-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8143288B2 (en)	2005-06-06	2012-03-27	Bristol-Myers Squibb Company	Inhibitors of HCV replication
US8329159B2 (en) *	2006-08-11	2012-12-11	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7659270B2 (en) *	2006-08-11	2010-02-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7759495B2 (en)	2006-08-11	2010-07-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8303944B2 (en) *	2006-08-11	2012-11-06	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
US7741347B2 (en) *	2007-05-17	2010-06-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2168959A1 (en) *	2007-06-19	2010-03-31	Kyorin Pharmaceutical Co., Ltd.	Pyridazinone derivative and pde inhibitor containing the same as active ingredient
US7728027B2 (en)	2007-08-08	2010-06-01	Bristol-Myers Squibb Company	Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en)	2007-08-08	2014-01-14	Bristol-Myers Squibb Company	Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
JP5314053B2 (ja)	2008-02-12	2013-10-16	ブリストル−マイヤーズスクイブカンパニー	Ｃ型肝炎ウイルス阻害剤
KR101492672B1 (ko)	2008-02-13	2015-02-16	브리스톨-마이어스 스큅 컴퍼니	Ｃ형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸
US7704992B2 (en) *	2008-02-13	2010-04-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8147818B2 (en)	2008-02-13	2012-04-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
GB2457659A (en)	2008-02-19	2009-08-26	Malcolm Mulheron	Foldable meal tray
WO2010004843A1 (ja)	2008-07-08	2010-01-14	Ntn株式会社	減速装置
US20110269734A1 (en)	2008-07-10	2011-11-03	Prosidion Limited	Piperidinyl gpcr agonists
US7906655B2 (en) *	2008-08-07	2011-03-15	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8383094B2 (en) *	2008-10-01	2013-02-26	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2010062821A1 (en)	2008-11-28	2010-06-03	Glaxosmithkline Llc	Anti-viral compounds, compositions, and methods of use
KR20110098779A (ko) *	2008-12-03	2011-09-01	프레시디오 파마슈티칼스, 인코포레이티드	Ｈｃｖｎｓ5ａ의 억제제
BRPI0922366B8 (pt) *	2008-12-03	2021-05-25	Presidio Pharmaceuticals Inc	composto, composição farmacêutica e uso de um composto
WO2010091413A1 (en)	2009-02-09	2010-08-12	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole derivatives
TWI438200B (zh)	2009-02-17	2014-05-21	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
WO2010096462A1 (en)	2009-02-17	2010-08-26	Enanta Pharmaceuticals, Inc	Linked diimidazole derivatives
WO2010094977A1 (en)	2009-02-23	2010-08-26	Arrow Therapeutics Limited	Novel biphenyl compounds useful for the treatment of hepatitis c
EP2398474A4 (en)	2009-02-23	2012-12-05	Presidio Pharmaceuticals Inc	HCV NS5A SHEMMER
KR101411889B1 (ko)	2009-02-27	2014-06-27	이난타 파마슈티칼스, 인코포레이티드	Ｃ형 간염 바이러스 억제제
KR20110128947A (ko)	2009-03-20	2011-11-30	앨리오스 바이오파마 인크.	치환된 뉴클레오시드 및 뉴클레오티드 유사체
SG174883A1 (en)	2009-03-27	2011-11-28	Presidio Pharmaceuticals Inc	Fused ring inhibitors of hepatitis c
EP2410841A4 (en)	2009-03-27	2012-10-24	Presidio Pharmaceuticals Inc	SUBSTITUTED BICYCLIC HCV INHIBITORS
KR20130140219A (ko)	2009-03-27	2013-12-23	머크 샤프 앤드 돔 코포레이션	Ｃ형 간염 바이러스 복제의 억제제
TWI476190B (zh) *	2009-03-30	2015-03-11	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
US8796466B2 (en) *	2009-03-30	2014-08-05	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TW201038559A (en)	2009-04-09	2010-11-01	Bristol Myers Squibb Co	Hepatitis C virus inhibitors
US8143414B2 (en)	2009-04-13	2012-03-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP5734956B2 (ja)	2009-04-15	2015-06-17	アッヴィ・インコーポレイテッド	抗ウィルス化合物
CN102414199B (zh)	2009-04-24	2014-03-05	泰博特克药品公司	二芳基醚
AU2010249080A1 (en) *	2009-05-12	2012-01-12	Merck Sharp & Dohme Corp.	Fused tricyclic aryl compounds useful for the treatment of viral diseases
RS56654B8 (sr) *	2009-05-13	2021-06-30	Gilead Pharmasset Llc	Antiviralna jedinjenja
US8138215B2 (en)	2009-05-29	2012-03-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8211928B2 (en)	2009-05-29	2012-07-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP2012528194A (ja)	2009-05-29	2012-11-12	メルク・シャープ・アンド・ドーム・コーポレーション	Ｃ型肝炎などの疾患を処置するための３つの整列型アリール部分で構成された抗菌性化合物
WO2010138791A1 (en)	2009-05-29	2010-12-02	Schering Corporation	Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
SG171708A1 (en) *	2009-06-11	2011-07-28	Abbott Lab	Anti-viral compounds to treat hcv infection
US8221737B2 (en) *	2009-06-16	2012-07-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
WO2010148006A1 (en)	2009-06-16	2010-12-23	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
WO2011004276A1 (en)	2009-07-06	2011-01-13	Pfizer Limited	Hepatitis c virus inhibitors
EP2454254A2 (en)	2009-07-16	2012-05-23	Vertex Pharmaceuticals Incorporated	Benzimidazole analogues for the treatment or prevention of flavivirus infections
AU2010280711A1 (en)	2009-08-07	2012-02-09	Janssen Sciences Ireland Uc	Phenyl ethynyl derivatives as hepatitis C virus inhibitors
AU2010280712B2 (en)	2009-08-07	2015-10-22	Janssen Sciences Ireland Uc	Bis-benzimidazole derivatives as hepatitis C virus inhibitors
FR2949465B1 (fr)	2009-09-01	2011-08-12	Pf Medicament	Derives chromones, leur procede de preparation et leurs applications therapeutiques
CA2772484A1 (en)	2009-09-03	2011-03-10	Tibotec Pharmaceuticals	Bis-benzimidazole derivatives
EP3006441A1 (en)	2009-09-04	2016-04-13	Janssen Pharmaceuticals, Inc.	Ns5a inhibitors
US9156818B2 (en)	2009-09-11	2015-10-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
EP2475254A4 (en)	2009-09-11	2013-05-22	Enanta Pharm Inc	HEPATITIS C-VIRUS HEMMER
US8415374B2 (en)	2009-10-12	2013-04-09	Bristol-Myers Squibb Company	Combinations of hepatitis C virus inhibitors
WO2011050146A1 (en)	2009-10-23	2011-04-28	Glaxosmithkline Llc	Chemical compounds
UA108211C2 (uk)	2009-11-04	2015-04-10	Янссен Рід Айрленд	Бензімідазолімідазольні похідні
US20110269956A1 (en)	2009-11-11	2011-11-03	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110274648A1 (en)	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110281910A1 (en)	2009-11-12	2011-11-17	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
CA2782024A1 (en)	2009-11-25	2011-06-03	Schering Corporation	Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20110137633A1 (en) *	2009-12-03	2011-06-09	Abbott Laboratories	Anti-viral compounds and methods of identifying the same
US8653070B2 (en) *	2009-12-14	2014-02-18	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CN102822175A (zh) *	2009-12-18	2012-12-12	埃迪尼克斯医药公司	5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
CN104530079B (zh)	2009-12-18	2017-10-20	北京凯因科技股份有限公司	C型肝炎病毒复制的新型抑制剂
JP2013515068A (ja)	2009-12-22	2013-05-02	メルク・シャープ・アンド・ドーム・コーポレーション	ウイルス性疾患の治療のための縮合三環式化合物およびその使用方法
US20130072523A1 (en)	2009-12-24	2013-03-21	Vertex Pharmaceuticals Incorporated	Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en)	2009-12-30	2013-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2011091446A1 (en)	2010-01-22	2011-07-28	Glaxosmithkline Llc	Chemical compounds
SG183526A1 (en)	2010-03-09	2012-09-27	Merck Sharp & Dohme	Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
US20110312996A1 (en)	2010-05-17	2011-12-22	Intermune, Inc.	Novel inhibitors of hepatitis c virus replication
WO2011146817A1 (en) *	2010-05-21	2011-11-24	Gilead Sciences, Inc.	Heterocyclic flaviviridae virus inhibitors
WO2011156757A1 (en) *	2010-06-10	2011-12-15	Gilead Sciences, Inc.	Combination of anti-hcv compounds with ribavirin for the treatment of hcv
US8859595B2 (en)	2010-08-26	2014-10-14	Rfs Pharma, Llc	Potent and selective inhibitors of hepatitis C virus
EP2621931A4 (en)	2010-09-29	2014-03-19	Merck Sharp & Dohme	TETRACYCLIC INDOLATE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION
WO2012048421A1 (en)	2010-10-14	2012-04-19	Boehringer Ingelheim International Gmbh	Hepatitis c inhibitor compounds
KR20190012271A (ko)	2010-11-17	2019-02-08	길리애드 파마셋 엘엘씨	항바이러스 화합물
CA2822037A1 (en)	2010-12-20	2012-06-28	Gilead Sciences, Inc.	Methods for treating hcv
WO2012087976A2 (en)	2010-12-21	2012-06-28	Intermune, Inc.	Novel inhibitors of hepatitis c virus replication
DE202012013074U1 (de) *	2011-09-16	2014-10-29	Gilead Pharmasset Lcc	Zusammensetzungen zur Behandlung von HCV
US20130164260A1 (en)	2011-11-16	2013-06-27	Gilead Sciences, Inc.	Antiviral compounds
US8969588B2 (en) *	2012-06-05	2015-03-03	Gilead Pharmasset Llc	Solid forms of an antiviral compound
US8841340B2 (en) *	2012-08-17	2014-09-23	Gilead Sciences, Inc.	Solid forms of an antiviral compound

2010
- 2010-05-12 RS RS20171281A patent/RS56654B8/sr unknown
- 2010-05-12 CA CA2761258A patent/CA2761258C/en active Active
- 2010-05-12 TW TW109105841A patent/TW202042807A/zh unknown
- 2010-05-12 TW TW103134406A patent/TWI547495B/zh active
- 2010-05-12 UA UAA201413049A patent/UA121454C2/uk unknown
- 2010-05-12 NZ NZ706236A patent/NZ706236A/en unknown
- 2010-05-12 EP EP14175539.7A patent/EP2873665B1/en active Active
- 2010-05-12 MX MX2011012058A patent/MX2011012058A/es active IP Right Grant
- 2010-05-12 ES ES14175539.7T patent/ES2596247T3/es active Active
- 2010-05-12 WO PCT/US2010/034600 patent/WO2010132601A1/en active Application Filing
- 2010-05-12 SG SG10201402280QA patent/SG10201402280QA/en unknown
- 2010-05-12 DK DK15180635.3T patent/DK3002281T3/en active
- 2010-05-12 TW TW099115093A patent/TWI465444B/zh active
- 2010-05-12 PT PT107209702T patent/PT2430014E/pt unknown
- 2010-05-12 SI SI201031950T patent/SI3309157T1/sl unknown
- 2010-05-12 LT LTEP14175539.7T patent/LT2873665T/lt unknown
- 2010-05-12 AR ARP100101639A patent/AR076765A1/es not_active Application Discontinuation
- 2010-05-12 KR KR1020147016501A patent/KR20140122705A/ko not_active Application Discontinuation
- 2010-05-12 EP EP17190692.8A patent/EP3309157B1/en active Active
- 2010-05-12 EP EP15180635.3A patent/EP3002281B1/en active Active
- 2010-05-12 KR KR1020147016504A patent/KR101503752B1/ko active IP Right Grant
- 2010-05-12 UY UY0001032629A patent/UY32629A/es not_active Application Discontinuation
- 2010-05-12 BR BRPI1010795A patent/BRPI1010795B1/pt active IP Right Grant
- 2010-05-12 EP EP19193481.9A patent/EP3626716A1/en not_active Withdrawn
- 2010-05-12 EA EA201190259A patent/EA021974B1/ru active Protection Beyond IP Right Term
- 2010-05-12 ME MEP-2016-215A patent/ME02536B/me unknown
- 2010-05-12 LT LTEP15180635.3T patent/LT3002281T/lt unknown
- 2010-05-12 KR KR1020187006008A patent/KR20180028070A/ko not_active Application Discontinuation
- 2010-05-12 EA EA201790515A patent/EA037281B1/ru unknown
- 2010-05-12 ES ES17190692T patent/ES2758726T3/es active Active
- 2010-05-12 PL PL14175539T patent/PL2873665T3/pl unknown
- 2010-05-12 BR BR122014013631A patent/BR122014013631B8/pt active IP Right Grant
- 2010-05-12 AP AP2011005987A patent/AP3622A/xx active
- 2010-05-12 ME MEP-2015-196A patent/ME02321B/me unknown
- 2010-05-12 HU HUE14175539A patent/HUE030465T2/hu unknown
- 2010-05-12 EA EA201490854A patent/EA026536B1/ru unknown
- 2010-05-12 RS RS20160824A patent/RS55249B8/sr unknown
- 2010-05-12 AU AU2010249043A patent/AU2010249043B2/en active Active
- 2010-05-12 MX MX2014006862A patent/MX363732B/es unknown
- 2010-05-12 MX MX2014005805A patent/MX360803B/es unknown
- 2010-05-12 SG SG2011083151A patent/SG176015A1/en unknown
- 2010-05-12 PL PL15180635T patent/PL3002281T3/pl unknown
- 2010-05-12 EA EA201490853A patent/EA201490853A1/ru unknown
- 2010-05-12 TW TW107113373A patent/TWI689305B/zh active
- 2010-05-12 EP EP20140175570 patent/EP2857394A1/en not_active Withdrawn
- 2010-05-12 CN CN201811070551.XA patent/CN109020961A/zh active Pending
- 2010-05-12 PE PE2011001965A patent/PE20120509A1/es active IP Right Grant
- 2010-05-12 KR KR1020197007083A patent/KR20190029771A/ko active Application Filing
- 2010-05-12 ES ES10720970.2T patent/ES2548156T3/es active Active
- 2010-05-12 CN CN201410227599.2A patent/CN104016971B/zh active Active
- 2010-05-12 US US12/779,023 patent/US8088368B2/en active Active
- 2010-05-12 PT PT141755397T patent/PT2873665T/pt unknown
- 2010-05-12 NZ NZ61920510A patent/NZ619205A/en unknown
- 2010-05-12 PE PE2014001982A patent/PE20150202A1/es active IP Right Grant
- 2010-05-12 KR KR1020207001908A patent/KR20200011049A/ko not_active Application Discontinuation
- 2010-05-12 NZ NZ596444A patent/NZ596444A/en unknown
- 2010-05-12 TW TW103134405A patent/TW201503888A/zh unknown
- 2010-05-12 ME MEP-2017-262A patent/ME02916B/me unknown
- 2010-05-12 DK DK10720970.2T patent/DK2430014T3/en active
- 2010-05-12 KR KR1020167017466A patent/KR101727876B1/ko active IP Right Grant
- 2010-05-12 AP AP2016008993A patent/AP2016008993A0/xx unknown
- 2010-05-12 PL PL10720970T patent/PL2430014T3/pl unknown
- 2010-05-12 JP JP2012510987A patent/JP5582662B2/ja active Active
- 2010-05-12 SI SI201031290T patent/SI2873665T1/sl unknown
- 2010-05-12 SI SI201031554T patent/SI3002281T1/sl unknown
- 2010-05-12 PL PL17190692T patent/PL3309157T3/pl unknown
- 2010-05-12 HU HUE10720970A patent/HUE025983T2/en unknown
- 2010-05-12 CN CN201611104976.9A patent/CN106588890B/zh active Active
- 2010-05-12 DK DK14175539.7T patent/DK2873665T3/en active
- 2010-05-12 PT PT151806353T patent/PT3002281T/pt unknown
- 2010-05-12 SI SI201031024T patent/SI2430014T1/sl unknown
- 2010-05-12 RS RS20150758A patent/RS54386B8/sr unknown
- 2010-05-12 CN CN201410227574.2A patent/CN104211713B/zh active Active
- 2010-05-12 TW TW105117036A patent/TWI629981B/zh active
- 2010-05-12 HU HUE15180635A patent/HUE036906T2/hu unknown
- 2010-05-12 CN CN201410226164.6A patent/CN103977406B/zh active Active
- 2010-05-12 PT PT171906928T patent/PT3309157T/pt unknown
- 2010-05-12 TW TW104133224A patent/TW201617073A/zh unknown
- 2010-05-12 KR KR1020117029699A patent/KR101546119B1/ko active Protection Beyond IP Right Term
- 2010-05-12 KR KR1020177009423A patent/KR20170041924A/ko not_active Application Discontinuation
- 2010-05-12 CN CN201410226959.7A patent/CN104211689B/zh active Active
- 2010-05-12 NO NO15180635A patent/NO3002281T3/no unknown
- 2010-05-12 CA CA2886322A patent/CA2886322A1/en not_active Abandoned
- 2010-05-12 EP EP10720970.2A patent/EP2430014B1/en active Active
- 2010-05-12 ES ES15180635.3T patent/ES2646131T3/es active Active
- 2010-05-12 EA EA201590073A patent/EA027493B1/ru unknown
- 2010-05-12 CN CN201080029503.1A patent/CN102596936B/zh active Active
- 2010-05-12 MX MX2014005933A patent/MX360800B/es unknown
- 2010-05-12 CN CN201410226767.6A patent/CN104230900B/zh active Active
- 2010-05-12 BR BR122014012810A patent/BR122014012810B1/pt active IP Right Grant
2011
- 2011-11-08 US US13/291,977 patent/US8273341B2/en active Active
- 2011-11-10 IL IL216254A patent/IL216254A/en active IP Right Grant
- 2011-11-11 MX MX2019003738A patent/MX2019003738A/es active IP Right Grant
- 2011-11-11 MX MX2020011251A patent/MX2020011251A/es unknown
- 2011-11-11 CL CL2011002825A patent/CL2011002825A1/es unknown
- 2011-11-17 ZA ZA2011/08436A patent/ZA201108436B/en unknown
- 2011-11-30 CO CO11164618A patent/CO6470842A2/es active IP Right Grant
- 2011-12-12 EC EC2011011517A patent/ECSP11011517A/es unknown
2012
- 2012-04-02 HK HK15108271.6A patent/HK1207638A1/zh unknown
- 2012-04-02 HK HK12103256.9A patent/HK1162518A1/zh unknown
- 2012-06-07 US US13/491,446 patent/US8669234B2/en active Active
- 2012-07-19 US US13/553,517 patent/US8575118B2/en active Active
2013
- 2013-07-31 US US13/956,195 patent/US8822430B2/en active Active
- 2013-10-03 US US14/045,717 patent/US8841278B2/en active Active
2014
- 2014-05-16 US US14/280,478 patent/US9511056B2/en active Active
- 2014-05-23 JP JP2014107359A patent/JP5744283B2/ja active Active
- 2014-06-10 IL IL233042A patent/IL233042A0/en unknown
- 2014-06-10 IL IL233044A patent/IL233044A/en active IP Right Grant
- 2014-06-17 JP JP2014124325A patent/JP5745727B2/ja active Active
- 2014-07-17 IL IL233679A patent/IL233679B/en active IP Right Grant
- 2014-07-17 IL IL233678A patent/IL233678B/en active IP Right Grant
2015
- 2015-04-28 JP JP2015091474A patent/JP2015157842A/ja not_active Withdrawn
- 2015-09-22 HR HRP20151000TT patent/HRP20151000T8/hr unknown
- 2015-11-17 CY CY20151101032T patent/CY1116942T1/el unknown
- 2015-11-19 SM SM201500284T patent/SMT201500284B/it unknown
2016
- 2016-01-07 HU HUS1600001C patent/HUS1600001I1/hu unknown
- 2016-01-11 LT LTPA2016002C patent/LTC2430014I2/lt unknown
- 2016-01-22 CY CY2016001C patent/CY2016001I2/el unknown
- 2016-02-05 FR FR16C0005C patent/FR16C0005I2/fr active Active
- 2016-02-17 NO NO2016004C patent/NO2016004I2/no not_active IP Right Cessation
- 2016-02-18 NL NL300796C patent/NL300796I2/nl unknown
- 2016-09-28 US US15/279,303 patent/US9981955B2/en active Active
- 2016-09-29 HR HRP20161242TT patent/HRP20161242T8/hr unknown
- 2016-10-04 CY CY20161100986T patent/CY1118048T1/el unknown
- 2016-10-05 SM SM201600351T patent/SMT201600351B/it unknown
- 2016-10-06 HK HK16111614.5A patent/HK1223365A1/zh unknown
2017
- 2017-05-12 JP JP2017095523A patent/JP2017145254A/ja not_active Withdrawn
- 2017-11-14 HR HRP20171759TT patent/HRP20171759T8/hr unknown
- 2017-12-06 CY CY20171101286T patent/CY1119684T1/el unknown
2018
- 2018-10-05 HK HK18112717.7A patent/HK1253517B/zh unknown
- 2018-12-25 JP JP2018240826A patent/JP2019104732A/ja not_active Withdrawn
2020
- 2020-09-24 JP JP2020159623A patent/JP2021001214A/ja active Pending
- 2020-12-18 NO NO2020046C patent/NO2020046I1/no unknown

Also Published As

Publication number	Publication date
PT3002281T (pt)	2017-11-14
MX2011012058A (es)	2012-04-02
CY1119684T1 (el)	2018-04-04
NL300796I2 (zh)	2016-06-30
HK1253517A1 (zh)	2019-06-21
CA2761258C (en)	2015-08-04
NO2020046I1 (no)	2020-12-18
EP3002281B1 (en)	2017-09-13
US8575118B2 (en)	2013-11-05
MX363732B (es)	2019-04-01
PL3309157T3 (pl)	2020-03-31
US20100310512A1 (en)	2010-12-09
LTC2430014I2 (lt)	2021-02-25
SI3309157T1 (sl)	2020-02-28
RS55249B8 (sr)	2021-06-30
HUS1600001I1 (hu)	2016-02-29
KR20200011049A (ko)	2020-01-31
ME02916B (me)	2018-10-20
ZA201108436B (en)	2013-01-30
EP2873665B1 (en)	2016-07-06
LT2873665T (lt)	2016-10-25
EP3626716A1 (en)	2020-03-25
BR122014012810A2 (pt)	2017-06-27
LTPA2016002I1 (lt)	2021-01-11
TWI629981B (zh)	2018-07-21
AP2016008993A0 (en)	2016-01-31
IL233042A0 (en)	2014-07-31
CN104211689A (zh)	2014-12-17
EP3309157B1 (en)	2019-09-04
US20170029408A1 (en)	2017-02-02
US8822430B2 (en)	2014-09-02
DK2430014T3 (en)	2015-11-30
KR20140122705A (ko)	2014-10-20
HRP20151000T8 (hr)	2021-05-14
SG10201402280QA (en)	2014-08-28
MX2019003738A (es)	2019-07-01
CN104211713A (zh)	2014-12-17
EP3309157A1 (en)	2018-04-18
EA201790515A1 (ru)	2018-10-31
US9981955B2 (en)	2018-05-29
NZ619205A (en)	2015-04-24
SI2873665T1 (sl)	2017-02-28
CN109020961A (zh)	2018-12-18
PE20150202A1 (es)	2015-02-13
US8841278B2 (en)	2014-09-23
MX360803B (es)	2018-11-16
HRP20161242T1 (hr)	2016-11-18
BRPI1010795A2 (pt)	2016-12-20
PT2873665T (pt)	2016-10-13
NO3002281T3 (zh)	2018-02-10
PT2430014E (pt)	2015-10-20
CN104211713B (zh)	2017-04-12
HUE025983T2 (en)	2016-05-30
US20140249074A1 (en)	2014-09-04
EA037281B1 (ru)	2021-03-04
NZ596444A (en)	2014-01-31
TWI547495B (zh)	2016-09-01
CY1118048T1 (el)	2018-03-07
CA2761258A1 (en)	2010-11-18
CN106588890B (zh)	2020-11-27
JP5744283B2 (ja)	2015-07-08
CL2011002825A1 (es)	2012-10-12
FR16C0005I2 (fr)	2016-09-30
JP2014169331A (ja)	2014-09-18
KR20140122706A (ko)	2014-10-20
KR20190029771A (ko)	2019-03-20
ME02536B (me)	2017-02-20
KR20170041924A (ko)	2017-04-17
JP2014148550A (ja)	2014-08-21
IL233044A0 (en)	2014-07-31
CN104016971B (zh)	2016-05-25
TW201504244A (zh)	2015-02-01
KR101727876B1 (ko)	2017-04-17
BR122014013631B1 (pt)	2020-11-17
EA201590073A1 (ru)	2015-06-30
US9511056B2 (en)	2016-12-06
US20120264711A1 (en)	2012-10-18
SMT201500284B (it)	2016-01-08
BR122014013631B8 (pt)	2021-11-23
HRP20171759T1 (hr)	2017-12-29
KR20160084478A (ko)	2016-07-13
HRP20161242T8 (hr)	2021-05-14
CN104230900B (zh)	2018-10-19
CN104211689B (zh)	2017-01-18
RS54386B8 (sr)	2021-06-30
PT3309157T (pt)	2019-12-02
AR076765A1 (es)	2011-07-06
ES2646131T3 (es)	2017-12-12
US8273341B2 (en)	2012-09-25
AP3622A (en)	2016-03-02
HUE030465T2 (hu)	2017-05-29
SMT201600351B (it)	2016-11-10
CN104230900A (zh)	2014-12-24
PL3002281T3 (pl)	2018-02-28
US20140051656A1 (en)	2014-02-20
CN104016971A (zh)	2014-09-03
RS56654B1 (sr)	2018-03-30
ES2596247T3 (es)	2017-01-05
EP2873665A1 (en)	2015-05-20
HK1162518A1 (zh)	2012-08-31
AU2010249043A1 (en)	2011-12-01
IL216254A (en)	2016-08-31
BRPI1010795B1 (pt)	2018-12-11
NO2016004I1 (no)	2016-02-17
TW201105656A (en)	2011-02-16
KR20140014393A (ko)	2014-02-06
HRP20151000T1 (hr)	2015-11-20
CN102596936A (zh)	2012-07-18
EA027493B1 (ru)	2017-07-31
SI3002281T1 (sl)	2017-11-30
US20120157404A1 (en)	2012-06-21
EP2430014A1 (en)	2012-03-21
ECSP11011517A (es)	2012-01-31
ME02321B (me)	2016-06-20
KR101503752B1 (ko)	2015-03-18
IL216254A0 (en)	2012-01-31
US20140039021A1 (en)	2014-02-06
IL233678B (en)	2019-05-30
FR16C0005I1 (zh)	2016-03-25
TW201902477A (zh)	2019-01-16
US8088368B2 (en)	2012-01-03
TW201503888A (zh)	2015-02-01
EP2430014B1 (en)	2015-08-19
EP3002281A1 (en)	2016-04-06
HRP20171759T8 (hr)	2021-05-14
MX2020011251A (es)	2020-11-12
IL233679B (en)	2019-05-30
CY1116942T1 (el)	2017-04-05
TW201632183A (zh)	2016-09-16
TW201617073A (zh)	2016-05-16
TWI689305B (zh)	2020-04-01
EP2857394A1 (en)	2015-04-08
ES2548156T3 (es)	2015-10-14
NO2016004I2 (no)	2016-02-29
IL233678A0 (en)	2014-09-30
US20130137877A1 (en)	2013-05-30
CY2016001I1 (el)	2018-01-10
SG176015A1 (en)	2011-12-29
IL233679A0 (en)	2014-09-30
KR101546119B1 (ko)	2015-08-20
CN103977406B (zh)	2016-10-19
CN102596936B (zh)	2014-06-11
UA121454C2 (uk)	2020-06-10
CY2016001I2 (el)	2018-01-10
CN103977406A (zh)	2014-08-13
PL2873665T3 (pl)	2017-01-31
RS55249B1 (sr)	2017-02-28
JP2017145254A (ja)	2017-08-24
UY32629A (es)	2010-12-31
JP5582662B2 (ja)	2014-09-03
RS56654B8 (sr)	2021-06-30
JP2012526838A (ja)	2012-11-01
JP5745727B2 (ja)	2015-07-08
ES2758726T3 (es)	2020-05-06
AP2011005987A0 (en)	2011-12-31
KR20180028070A (ko)	2018-03-15
IL233044A (en)	2015-07-30
HK1223365A1 (zh)	2017-07-28
BR122014013631A2 (pt)	2017-06-27
TW202042807A (zh)	2020-12-01
LT3002281T (lt)	2017-12-11
HK1207638A1 (zh)	2016-02-05
PE20120509A1 (es)	2012-05-09
DK2873665T3 (en)	2016-11-07
BR122014012810B1 (pt)	2020-04-14
CA2886322A1 (en)	2010-11-18
EA201490854A1 (ru)	2014-09-30
DK3002281T3 (en)	2017-12-18
PL2430014T3 (pl)	2016-02-29
HUE036906T2 (hu)	2018-08-28
JP2021001214A (ja)	2021-01-07
MX360800B (es)	2018-11-16
NZ706236A (en)	2016-07-29
EA201190259A1 (ru)	2013-01-30
EA201490853A1 (ru)	2014-09-30
AU2010249043B2 (en)	2014-10-09
EA021974B1 (ru)	2015-10-30
SI2430014T1 (sl)	2015-10-30
TWI465444B (zh)	2014-12-21
WO2010132601A1 (en)	2010-11-18
EA026536B1 (ru)	2017-04-28
US8669234B2 (en)	2014-03-11
CO6470842A2 (es)	2012-06-29
JP2015157842A (ja)	2015-09-03
CN106588890A (zh)	2017-04-26
JP2019104732A (ja)	2019-06-27
RS54386B1 (en)	2016-04-28

Publication	Publication Date	Title
HK1253517B (zh)	2020-04-24	抗病毒化合物
IL219965A0 (en)	2012-07-31	Novel antiviral compounds
IL216026A0 (en)	2012-01-31	Heterocyckic antiviral compounds
GB0906209D0 (en)	2009-05-20	Antiviral compounds
GB0914473D0 (en)	2009-09-30	Antiviral compounds
GB0908677D0 (en)	2009-08-12	Antiviral compounds
GB0922520D0 (en)	2010-02-10	Novel antiviral compounds